Neal Rosen

Citada per

	Totes	Des de 2020
Citacions	65693	18800
Índex h	136	71
Índex i10	282	188

4000

2000

1000

3000

199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025169 255 275 272 309 268 272 282 415 444 540 586 681 1044 1214 1215 1413 1551 1672 1928 2069 2454 3015 3421 3454 3365 3328 3203 3203 3391 3517 3966 3839 3463 3534 464

Accés públic

Mostra-ho tot

126 articles

1 article

disponibles

no disponibles

Es basa en els requisits de les agències que proporcionen el finançament

Coautors

David SolitCo-Director, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterCorreu electrònic verificat a mskcc.org
Sarat ChandarlapatyMember, Memorial Sloan Kettering Cancer CenterCorreu electrònic verificat a mskcc.org
Christine Anne PratilasJohns Hopkins UniversityCorreu electrònic verificat a jhmi.edu
Poulikos I. PoulikakosIcahn School of Medicine at Mount SinaiCorreu electrònic verificat a mssm.edu
Laura Sepp-LorenzinoIntellia TherapeuticsCorreu electrònic verificat a intelliatx.com
Qing-Bai SheProfessor of Molecular Pharmacology, University of KentuckyCorreu electrònic verificat a uky.edu
Gabriela ChiosisProfessor, Memorial Sloan KetteringCorreu electrònic verificat a mskcc.org
Maurizio ScaltritiAstraZenecaCorreu electrònic verificat a astrazeneca.com
Pamela MunsterUCSFCorreu electrònic verificat a ucsf.edu
Rona YaegerMemorial Sloan Kettering Cancer CenterCorreu electrònic verificat a mskcc.org
Zhan YaoLoxo oncology at LillyCorreu electrònic verificat a loxooncology.com
Taha MerghoubAssociate Professor, MSKCorreu electrònic verificat a mskcc.org
Douglas YeeProfessor of MedicineCorreu electrònic verificat a umn.edu
shanu modiAssociate, Memorial Sloan Kettering Cancer CenterCorreu electrònic verificat a mskcc.org
Agnes VialeMemorial Sloan Kettering Cancer CenterCorreu electrònic verificat a mskcc.org
Charles SawyersMemorial Sloan Kettering Cancer CenterCorreu electrònic verificat a mskcc.org
Michael F BergerMember, Memorial Sloan-Kettering Cancer CenterCorreu electrònic verificat a mskcc.org
Madhavi TadiMSKCC,Mayo clinic, Biogen,University of MiamiCorreu electrònic verificat a med.miami.edu
Manickam JanakiramanResearch Associate, Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan-Kettering Cancer Center (MSKCC)Correu electrònic verificat a mskcc.org
Violeta Serra, PhDPrincipal InvestigatorCorreu electrònic verificat a vhio.net

Segueix

Neal Rosen

Professor of Pharmacology, Memorial Sloan-Kettering Cancer Center

Correu electrònic verificat a mskcc.org

Cancer Biology


Títol Ordena per cites Ordena per any Ordena per títol	Citada per Citada per	Any
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt KE O'Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, ... Cancer research 66 (3), 1500-1508, 2006	3025	2006
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF PI Poulikakos, C Zhang, G Bollag, KM Shokat, N Rosen Nature 464 (7287), 427-430, 2010	2075	2010
Crystal structure of an Hsp90–geldanamycin complex: targeting of a protein chaperone by an antitumor agent CE Stebbins, AA Russo, C Schneider, N Rosen, FU Hartl, NP Pavletich Cell 89 (2), 239-250, 1997	1759	1997
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387-390, 2011	1692	2011
BRAF mutation predicts sensitivity to MEK inhibition DB Solit, LA Garraway, CA Pratilas, A Sawai, G Getz, A Basso, Q Ye, ... Nature 439 (7074), 358-362, 2006	1562	2006
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer BS Carver, C Chapinski, J Wongvipat, H Hieronymus, Y Chen, ... Cancer cell 19 (5), 575-586, 2011	1349	2011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ... Cancer cell 19 (1), 58-71, 2011	1098	2011
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function AD Basso, DB Solit, G Chiosis, B Giri, P Tsichlis, N Rosen Journal of Biological Chemistry 277 (42), 39858-39866, 2002	793	2002
Clinical sequencing defines the genomic landscape of metastatic colorectal cancer R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ... Cancer cell 33 (1), 125-136. e3, 2018	768	2018
Targeted drug delivery strategies for precision medicines MT Manzari, Y Shamay, H Kiguchi, N Rosen, M Scaltriti, DA Heller Nature Reviews Materials 6 (4), 351-370, 2021	720	2021
V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway CA Pratilas, BS Taylor, Q Ye, A Viale, C Sander, DB Solit, N Rosen Proceedings of the National Academy of Sciences 106 (11), 4519-4524, 2009	698	2009
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism P Lito, M Solomon, LS Li, R Hansen, N Rosen Science 351 (6273), 604-608, 2016	694	2016
Tumor adaptation and resistance to RAF inhibitors P Lito, N Rosen, DB Solit Nature medicine 19 (11), 1401-1409, 2013	691	2013
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway RC Muise-Helmericks, HL Grimes, A Bellacosa, SE Malstrom, PN Tsichlis, ... Journal of Biological Chemistry 273 (45), 29864-29872, 1998	690	1998
The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells MM Moasser, A Basso, SD Averbuch, N Rosen Cancer research 61 (19), 7184-7188, 2001	663	2001
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress P Workman, F Burrows, LEN Neckers, N Rosen Annals of the New York Academy of Sciences 1113 (1), 202-216, 2007	662	2007
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity LH Saal, P Johansson, K Holm, SK Gruvberger-Saal, QB She, M Maurer, ... Proceedings of the National Academy of Sciences 104 (18), 7564-7569, 2007	644	2007
The advantages of targeted protein degradation over inhibition: an RTK case study GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ... Cell chemical biology 25 (1), 67-77. e3, 2018	624	2018
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ... Oncogene 30 (22), 2547-2557, 2011	623	2011
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ... Cancer cell 22 (5), 668-682, 2012	621	2012

En aquests moments el sistema no pot dur a terme l'operació. Torneu-ho a provar més tard.

Articles 1–20

Cites per any

Cites duplicades

Cites combinades

Addició de coautorsCoautors

Segueix

Citada per

Coautors